Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

NCT03241186 is registered in ClinicalTrials.gov with Robert R. McWilliams, MD as lead sponsor.

NCT NCT03241186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03241186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Lead sponsor
Robert R. McWilliams, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 12, 2017
Completion date
September 30, 2023
Enrollment
36 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

mucosal melanoma